Qiagen (QGEN) has released an update.
Qiagen N.V. announced its Q1 2024 financial results, surpassing its sales outlook with $462 million at constant exchange rates, while maintaining a strong adjusted operating income margin of 25.7%. Despite a 5% decline in sales, the company has upheld its full-year guidance with expected net sales of at least $2.0 billion and adjusted diluted EPS of at least $2.10. Highlighting resilience amidst a tough economic environment, Qiagen’s diagnostics and efficiency gains continue to drive growth and investor confidence.
For further insights into QGEN stock, check out TipRanks’ Stock Analysis page.
